Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Mark Winderlich"'
Autor:
Grzegorz S. Nowakowski, Mark Winderlich, Sumeet Ambarkhane, Günter Fingerle-Rowson, Debarshi Dey, Stephan Parche, Sascha Tillmanns, Nuwan C. Kurukulasuriya, Bruce Feinberg, Gilles Salles, Nathan H. Fowler, Erika Meli, Claudia Castellino, Anna Maria Barbui, Maurizio Frezzato, Dario Marino, Thomas Rodgers, Pier Luigi Zinzani
Supplementary Methods, Tables, and Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cd5b909d20f5f86c1b0721fbf284605
https://doi.org/10.1158/1078-0432.23183827
https://doi.org/10.1158/1078-0432.23183827
Autor:
Grzegorz S. Nowakowski, Mark Winderlich, Sumeet Ambarkhane, Günter Fingerle-Rowson, Debarshi Dey, Stephan Parche, Sascha Tillmanns, Nuwan C. Kurukulasuriya, Bruce Feinberg, Gilles Salles, Nathan H. Fowler, Erika Meli, Claudia Castellino, Anna Maria Barbui, Maurizio Frezzato, Dario Marino, Thomas Rodgers, Pier Luigi Zinzani
Purpose:Tafasitamab, an Fc-modified, humanized, anti-CD19 monoclonal antibody, in combination with lenalidomide, demonstrated efficacy in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), in the sing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a29b8d138b8ff55969aafd4e29ede446
https://doi.org/10.1158/1078-0432.c.6664573.v1
https://doi.org/10.1158/1078-0432.c.6664573.v1
Autor:
Grzegorz S. Nowakowski, Dok Hyun Yoon, Patrizia Mondello, Erel Joffe, Anthea Peters, Isabelle Fleury, Richard Greil, Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Zinzani, Judith Trotman, Lorenzo Sabatelli, Eva E. Waltl, Mark Winderlich, Andrea Sporchia, Nuwan C. Kurukulasuriya, Raul Cordoba, Georg Hess, Gilles Salles
Publikováno v:
Annals of Hematology.
Abstract RE-MIND2 (NCT04697160) compared patient outcomes from the L-MIND (NCT02399085) trial of tafasitamab+lenalidomide with those of patients treated with other therapies for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::272f3372021f75cc377a67622654a660
https://doi.org/10.1007/s00277-023-05196-4
https://doi.org/10.1007/s00277-023-05196-4
Autor:
Grzegorz S. Nowakowski, Dok Hyun Yoon, Anthea Peters, Patrizia Mondello, Erel Joffe, Isabelle Fleury, Richard Greil, Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Zinzani, Judith Trotman, Dan Huang, Eva E. Waltl, Mark Winderlich, Nuwan C. Kurukulasuriya, Sumeet Ambarkhane, Georg Hess, Gilles Salles
Publikováno v:
Clinical Cancer Research. 28:4003-4017
Purpose: In RE-MIND2 (NCT04697160), patient-level outcomes from the L-MIND study (NCT02399085) of tafasitamab plus lenalidomide were retrospectively compared with patient-level matched observational cohorts treated with National Cancer Care Network (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ebab011fbb0db0e241089a4a48e57884
https://doi.org/10.1158/1078-0432.ccr-21-3648
https://doi.org/10.1158/1078-0432.ccr-21-3648
Autor:
Gilles Salles, Georg Hess, Sumeet Ambarkhane, Nuwan C. Kurukulasuriya, Mark Winderlich, Eva E. Waltl, Dan Huang, Judith Trotman, Pier Luigi Zinzani, Kibum Kim, Reinhard Marks, Matthew Ku, Richard Greil, Isabelle Fleury, Erel Joffe, Patrizia Mondello, Anthea Peters, Dok Hyun Yoon, Grzegorz S. Nowakowski
Supplementary Data from Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1930e700e550408af15df231fb5a4638
https://doi.org/10.1158/1078-0432.22487384
https://doi.org/10.1158/1078-0432.22487384
Autor:
Gilles Salles, Georg Hess, Sumeet Ambarkhane, Nuwan C. Kurukulasuriya, Mark Winderlich, Eva E. Waltl, Dan Huang, Judith Trotman, Pier Luigi Zinzani, Kibum Kim, Reinhard Marks, Matthew Ku, Richard Greil, Isabelle Fleury, Erel Joffe, Patrizia Mondello, Anthea Peters, Dok Hyun Yoon, Grzegorz S. Nowakowski
Supplementary Figure from Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac633b966e25188b2e8278adf36a2753
https://doi.org/10.1158/1078-0432.22487378
https://doi.org/10.1158/1078-0432.22487378
Autor:
Gilles Salles, Georg Hess, Sumeet Ambarkhane, Nuwan C. Kurukulasuriya, Mark Winderlich, Eva E. Waltl, Dan Huang, Judith Trotman, Pier Luigi Zinzani, Kibum Kim, Reinhard Marks, Matthew Ku, Richard Greil, Isabelle Fleury, Erel Joffe, Patrizia Mondello, Anthea Peters, Dok Hyun Yoon, Grzegorz S. Nowakowski
Purpose:In RE-MIND2 (NCT04697160), patient-level outcomes from the L-MIND study (NCT02399085) of tafasitamab plus lenalidomide were retrospectively compared with patient-level matched observational cohorts treated with National Cancer Care Network (N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33449120f3d5064cb2e5d1c9a51e9be6
https://doi.org/10.1158/1078-0432.c.6532508
https://doi.org/10.1158/1078-0432.c.6532508
Autor:
Mark Winderlich, Sumeet Ambarkhane, Wolfram Brugger, Maren Dirnberger-Hertweck, Wing Hang Leung, Elias Jabbour, Rebecca B. Klisovic
Publikováno v:
Cancer. 127:4190-4197
BACKGROUND B-precursor cell acute lymphoblastic leukemia (B-ALL) in adults is an aggressive and challenging condition, and patients with relapsed/refractory (R/R) disease after allogeneic stem cell transplantation (SCT), or noncandidates for SCT, hav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e9c9064b6fc78df1ea4d223c39000df
https://doi.org/10.1002/cncr.33796
https://doi.org/10.1002/cncr.33796
Autor:
Antje Blank, Hartmut Goldschmidt, Stefan Härtle, Igor Wolfgang Blau, Tiantom Jarutat, Hermann Einsele, Katja Weisel, Manik Chatterjee, Christoph Röllig, Marc S. Raab, Johannes Weirather, Janine Griese, Christian Peschel, Monika Engelhardt, Hermine Agis, Barbara Ferstl, Mark Winderlich, Natalie Schub
Publikováno v:
The Lancet Haematology. 7:e381-e394
Summary Background Treatment of multiple myeloma is not curative, but targeting CD38 improves patient survival. To further explore this therapeutic approach, we investigated the safety and activity of MOR202, a novel monoclonal antibody targeting CD3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d5f8163ef217b452c43baf28380e917
https://doi.org/10.1016/s2352-3026(19)30249-2
https://doi.org/10.1016/s2352-3026(19)30249-2
Autor:
Vincenzo Bagnardi, Dan Huang, Debarshi Dey, Mark Winderlich, G.S. Nowakowski, Gilles Salles, B Goswami, Sumeet Ambarkhane
Publikováno v:
Hematological Oncology. 39
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ddc324c08985699083bcb2a89d60ce92
https://doi.org/10.1002/hon.90_2880
https://doi.org/10.1002/hon.90_2880